阿达木单抗治疗幼年特发性关节炎相关葡萄膜炎的成本效果分析
基于SYCAMORE试验与决策分析模型,评估阿达木单抗联合甲氨蝶呤对比单用甲氨蝶呤治疗幼年特发性关节炎相关葡萄膜炎的成本效果。结论认为阿达木单抗临床有效但成本效果未获证实。
核心结论
- 阿达木单抗联合甲氨蝶呤治疗幼年特发性关节炎相关葡萄膜炎临床有效,但在英国背景下对比单用甲氨蝶呤未显示成本效果。
研究设计与样本
- 基于SYCAMORE临床试验与决策分析模型开展的成本效用分析。
- 研究对象为2至18岁、经优化甲氨蝶呤治疗至少12周仍持续活动性幼年特发性关节炎相关葡萄膜炎的儿童和青少年。
- 试验中甲氨蝶呤剂量至每周25 mg,阿达木单抗每两周给药20或40 mg(按体重)。
- 资源使用基于患者自我报告和电子记录,健康效用来自Health Utilities Index问卷。
- 手术事件率和长期结局基于10年纵向队列数据,采用Markov模型外推视觉损害相关效应。
关键数值与推荐
- 主要结局指标为英国国家卫生服务体系医疗成本、定义健康状态的效用、质量调整生命年(QALY)及每QALY增量成本。
- 阈值分析显示阿达木单抗需降价84%才具有成本效果。
临床怎么用
- 在考虑阿达木单抗用于幼年特发性关节炎相关葡萄膜炎时,需结合其临床有效性与英国背景下未达成本效果阈值的经济学证据综合决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the cost effectiveness of adalimumab in combination with methotrexate, compared with methotrexate alone, for the management of uveitis associated with juvenile idiopathic arthritis (JIA). DESIGN: A cost-utility analysis based on a clinical trial and decision analytic model. PARTICIPANTS: Children and adolescents 2 to 18 years of age with persistently active uveitis associated with JIA, despite optimized methotrexate treatment for at least 12 weeks. METHODS: The SYCAMORE (Randomised controlled trial of the clinical effectiveness, SafetY and Cost effectiveness of Adalimumab in combination with MethOtRExate for the treatment of juvenile idiopathic arthritis associated uveitis) trial (identifier, ISRCTN10065623) of methotrexate (up to 25 mg weekly) with or without fortnightly administered adalimumab (20 or 40 mg, according to body weight) provided data on resource use (based on patient self-report and electronic records) and health utilities (from the Health Utilities Index questionnaire). Surgical event rates and long-term outcomes were based on data from a 10-year longitudinal cohort. A Markov model was used to extrapolate the effects of treatment based on visual impairment. MAIN OUTCOME MEASURES: Medical costs to the National Health Service in the United Kingdom, utility of defined health states, quality-adjusted life-years (QALYs), and incremental cost per QALY. RESULTS: Adalimumab in combination with methotrexate resulted in additional costs of £39 316, with a 0.30 QALY gain compared with methotrexate alone, resulting in an incremental cost-effectiveness ratio of £129 025 per QALY gained. The probability of cost effectiveness at a threshold of £30 000 per QALY was less than 1%. Based on a threshold analysis, a price reduction of 84% would be necessary for adalimumab to be cost effective. CONCLUSIONS: Adalimumab is clinically effective in uveitis associated with JIA; however, its cost effectiveness is not demonstrated compared with methotrexate alone in the United Kingdom setting.
引用
- Hughes DA, Culeddu G, Plumpton CO, et al. Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis. Ophthalmology. 2018. PMID: 30336181. doi:10.1016/j.ophtha.2018.09.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。